12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Baricitinib: Phase III started

Incyte disclosed in its 3Q12 earnings that Eli Lilly began the double-blind, placebo-controlled, international Phase III RA-BEAM trial to compare 4 mg oral baricitinib once daily for 52 weeks vs. 40 mg subcutaneous adalimumab every 2 weeks in about 1,280 patients with moderately or severely active RA who have are resistant to methotrexate. Patients will continue to...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >